The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)
Authors:
- John R. YannelliJYJohn R. Yannelli
- Jamie SturgillJSJamie Sturgill
- Terry FoodyTFTerry Foody
- Edward HirschowitzEHEdward Hirschowitz
- 1 March 2005
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 47 (3) , 337-350
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Autologous Dendritic Cell Vaccines for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Growth and Functional Reactivity of Lymphocytes Obtained from Three Anatomic Compartments in Patients with Non–Small-Cell Lung Cancer (NSCLC)Cancer Biotherapy and Radiopharmaceuticals, 2003
- Survivin gene expression in early‐stage non‐small cell lung cancerThe Journal of Pathology, 2003
- Dendritic CellsAnnals of the New York Academy of Sciences, 2003
- Tumor-Associated Macrophages as a Source of Functional Dendritic Cells in Ovarian Cancer PatientsClinical Immunology, 2002
- Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patientsBlood, 2002
- Broadsheet: Dendritic cells and their emerging clinical applicationsPathology, 2001
- Generation of Monocyte-Derived Dendritic Cells From Patients With Renal Cell Cancer: Modulation of Their Functional Properties After Therapy With Biological Response Modifiers (IFN-α plus IL-2 and IL-12)Journal of Immunotherapy, 2000
- Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2JNCI: Journal of the National Cancer Institute, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.Journal of Experimental Medicine, 1994